Angiocidin inhibits breast cancer proliferation through activation of epidermal growth factor receptor and nuclear...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Angiocidin is a known tumor-associated peptide that inhibits tumor progression by blocking angiogenesis.
• The direct impact of angiocidin on tumor cell proliferation requires further elucidation.

Purpose of the Study:

• To investigate the direct anti-proliferative effects of angiocidin on breast cancer cells.
• To identify the molecular mechanisms underlying angiocidin's anti-proliferative action, including its interaction with the epidermal growth factor receptor (EGFR) and nuclear factor kappa B (NF-κB) pathways.

Main Methods:

• Utilized MDA-MB-231 breast cancer cells and angiocidin transfection models.
• Assessed cell proliferation in vitro and tumor development in vivo.
• Employed EGFR tyrosine kinase inhibitor 4557W to probe the role of EGFR.
• Analyzed EGFR phosphorylation using a human EGFR phosphorylation array.
• Investigated NF-κB activation and downstream gene expression.

Main Results:

• Angiocidin directly inhibited proliferation of MDA-MB-231 breast cancer cells, an effect reversed by an EGFR inhibitor.
• Angiocidin-transfected cells showed reduced proliferation in vitro and tumor growth in vivo.
• Angiocidin treatment increased EGFR tyrosine 845 phosphorylation, suggesting specific EGFR pathway activation.
• Angiocidin activated NF-κB, leading to the upregulation of genes including the cell cycle inhibitor p21(waf1).

Conclusions:

• Angiocidin possesses a direct anti-proliferative effect on breast cancer cells, independent of its anti-angiogenic properties.
• The anti-proliferative mechanism involves the activation of EGFR signaling and NF-κB pathway.
• Angiocidin represents a promising therapeutic peptide targeting both angiogenesis and direct tumor growth.